Sign inJoin waitlistJoin the waitlist

Michael Cameron

Physician · Cameron Dermatology Pllc

Credentials: · · · ·

History

Cameron Dermatology Pllc
2025–Present

University of Colorado School of Medicine
2016–2019
Memorial Sloan Kettering Cancer Center
2015–2016
University of South Florida College of Medicine
2011–2015
Duke University
2007–2011

Research

Basal cell carcinoma: Epidemiology; pathophysiology; clinical and histological subtypes; and disease associations
Review · Journal of the American Academy of Dermatology · 2019 · First of 8 authors · 365 citations
Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: Results from the JAK1 Atopic Dermatitis Efficacy and Safety…
Journal of the American Academy of Dermatology · 2022 · 126 citations
Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis
Systematic review or meta-analysis · Journal of the European Academy of Dermatology and Venereology · 2021 · 119 citations

HV
Hernan Valdez
6 papers
Mark Lebwohl
6 papers
Ramin Fathi
5 papers · 4 as a fellow
Jonathan Silverberg
4 papers
Eric Simpson
3 papers
Theo Alkousakis
3 papers
Alexandra Golant
2 papers
AS
Andrea Suarez
2 papers · 2 as a resident
AB
Andrew Blauvelt
2 papers
AR
Anthony Rossi
2 papers
BH
Brian Hibler
2 papers · 2 as a resident
Bruce Strober
2 papers

Clinical trials

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
Site PI · Recruiting · Phase 3
Novartis Pharmaceuticals
2026–2031
A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)
Site PI · Recruiting · Phase 4
Eli Lilly and Company
2025–2028